SI9011773B - Vaccine against lyme disease, process for obtaining it, monoclonal antibody, antigene, recombinant dna, recombinant vector and process for obtaining this antigene - Google Patents
Vaccine against lyme disease, process for obtaining it, monoclonal antibody, antigene, recombinant dna, recombinant vector and process for obtaining this antigene Download PDFInfo
- Publication number
- SI9011773B SI9011773B SI9011773A SI9011773A SI9011773B SI 9011773 B SI9011773 B SI 9011773B SI 9011773 A SI9011773 A SI 9011773A SI 9011773 A SI9011773 A SI 9011773A SI 9011773 B SI9011773 B SI 9011773B
- Authority
- SI
- Slovenia
- Prior art keywords
- antigen
- burgdorferi
- obtaining
- antigene
- lyme disease
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 6
- 108020004511 Recombinant DNA Proteins 0.000 title claims 2
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 208000016604 Lyme disease Diseases 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 claims abstract 13
- 102000036639 antigens Human genes 0.000 claims abstract 13
- 108091007433 antigens Proteins 0.000 claims abstract 13
- 241000589969 Borreliella burgdorferi Species 0.000 claims abstract 5
- 108700006640 OspA Proteins 0.000 claims abstract 4
- 238000010171 animal model Methods 0.000 claims abstract 4
- 241000448699 Borrelia burgdorferi ZS7 Species 0.000 claims abstract 3
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 102000005936 beta-Galactosidase Human genes 0.000 claims 1
- 108010005774 beta-Galactosidase Proteins 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 229940042470 lyme disease vaccine Drugs 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 abstract 3
- 206010062746 Carditis Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 210000004408 hybridoma Anatomy 0.000 abstract 1
- 230000008105 immune reaction Effects 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1207—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE3931236 | 1989-09-19 | ||
DE4015911A DE4015911A1 (de) | 1989-09-19 | 1990-05-17 | Impfstoff gegen die lyme-krankheit |
YU177390A YU48250B (sh) | 1989-09-19 | 1990-09-18 | Postupak za pripremanje aktivne vakcine protiv lajmske bolesti |
Publications (2)
Publication Number | Publication Date |
---|---|
SI9011773A SI9011773A (sl) | 1998-04-30 |
SI9011773B true SI9011773B (en) | 2001-12-31 |
Family
ID=25885304
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI9011773A SI9011773B (en) | 1989-09-19 | 1990-09-18 | Vaccine against lyme disease, process for obtaining it, monoclonal antibody, antigene, recombinant dna, recombinant vector and process for obtaining this antigene |
Country Status (24)
Country | Link |
---|---|
US (6) | US5178859A (sh) |
EP (5) | EP0643974B1 (sh) |
JP (3) | JP3205932B2 (sh) |
KR (2) | KR100205462B1 (sh) |
AT (4) | ATE191499T1 (sh) |
AU (1) | AU651560B2 (sh) |
CA (1) | CA2025597C (sh) |
CZ (2) | CZ284538B6 (sh) |
DE (5) | DE4015911A1 (sh) |
DK (4) | DK0418827T3 (sh) |
ES (4) | ES2082812T3 (sh) |
FI (1) | FI102248B1 (sh) |
GR (3) | GR3018995T3 (sh) |
HK (2) | HK1002405A1 (sh) |
HR (1) | HRP940545B1 (sh) |
HU (2) | HU212716B (sh) |
IE (1) | IE903377A1 (sh) |
NO (2) | NO311767B1 (sh) |
NZ (1) | NZ235260A (sh) |
PL (2) | PL170229B1 (sh) |
PT (1) | PT95349B (sh) |
SI (1) | SI9011773B (sh) |
SK (3) | SK283089B6 (sh) |
YU (2) | YU48250B (sh) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK590288D0 (da) | 1988-10-24 | 1988-10-24 | Symbicom Ab | Kemiske forbindelser |
US6143872A (en) * | 1988-10-24 | 2000-11-07 | Symbicom Aktiebolag | Borrelia burdorferi Osp A and B proteins and immunogenic peptides |
US7094391B1 (en) * | 1988-10-24 | 2006-08-22 | The University Of Texas System | Compositions and methods for administering Borrelia burgdorferi antigens |
US5777095A (en) * | 1988-10-24 | 1998-07-07 | Symbicom Aktiebolag | Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90 |
DE4015911A1 (de) * | 1989-09-19 | 1991-03-28 | Max Planck Gesellschaft | Impfstoff gegen die lyme-krankheit |
US5582829A (en) * | 1990-04-05 | 1996-12-10 | Rx Technologies, Inc. | Sonicated borrelia burgdorferi vaccine |
SG47447A1 (en) | 1990-06-15 | 1998-04-17 | Univ Yale | Compositions and methods for the prevention and diagnosis of lyme disease |
ATE196425T1 (de) * | 1990-07-06 | 2000-10-15 | American Home Prod | Impfstoff gegen die lyme-krankheit |
CA2057536C (en) * | 1990-12-21 | 1999-10-26 | John J. Dunn | Cloning and expression of borrelia lipoproteins |
US6872550B1 (en) | 1991-07-11 | 2005-03-29 | Baxter Vaccine Ag | Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens |
US6221363B1 (en) * | 1991-07-11 | 2001-04-24 | Baxter Aktiengesellschaft | Vaccine for the prevention of lyme disease |
US6676942B1 (en) | 1991-08-15 | 2004-01-13 | Smithkline Beecham Biologicals (S.A.) | Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines |
EP0877085A1 (en) * | 1991-08-15 | 1998-11-11 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | OspA protein of borrelia burgdorferi subgroups, encoding genes and vaccines |
WO1993008299A1 (en) * | 1991-10-18 | 1993-04-29 | Connaught Laboratories Inc. | Preparation of recombinant borrelia proteins |
EP0540457A1 (en) * | 1991-10-22 | 1993-05-05 | Symbicom Ab | Improvements in Borrelia burgdorferi diagnosis and prophylaxis |
US6303129B1 (en) * | 1992-07-28 | 2001-10-16 | Rx Technologies | Production of borrelia burgdorferi vaccine, product produced thereby and method of use |
US5656451A (en) * | 1993-07-30 | 1997-08-12 | Yale University | OspE, OspF, and S1 polypeptides in borrelia burgdorferi |
US6716591B1 (en) | 1993-07-30 | 2004-04-06 | Yale University | B. burgdorferi polypeptides |
US7008625B2 (en) | 1993-11-01 | 2006-03-07 | Research Foundation Of The State University Of New York | Recombinant constructs of Borrelia burgdorferi |
US5558993A (en) * | 1994-06-17 | 1996-09-24 | The Regents Of The University Of California | Cloned Borrelia burgdorferi virulence protein |
GB9511909D0 (en) * | 1995-06-12 | 1995-08-09 | Microbiological Res Authority | Vaccine |
US6437116B1 (en) | 1996-02-21 | 2002-08-20 | Board Of Regents, The University Of Texas System | VMP-like sequences of pathogenic borrelia |
DE19632862B4 (de) | 1996-08-14 | 2006-08-03 | Mikrogen Molekularbiologische Entwicklungs-Gmbh | Immunologisch aktive Proteine von Borrelia burgdorferi, dafür kodierende Nukleinsäuren sowie deren Verwendung in Testkits und als Impfstoffe |
US6458555B1 (en) * | 1996-08-21 | 2002-10-01 | Gerd Bach | Cytologic method of examining mucous membranes |
US6060082A (en) * | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
DE19740735A1 (de) * | 1997-09-16 | 1999-03-18 | Max Planck Gesellschaft | Arzneimittel zur Therapie einer manifesten Lyme-Borreliose |
US6306623B1 (en) * | 1998-02-24 | 2001-10-23 | The University Of California | Leptospiral major outer membrane protein LipL32 |
WO2000006745A1 (en) | 1998-07-31 | 2000-02-10 | Gundersen Lutheran Medical Foundation, Inc. | Uses of the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein c (ospc) as vaccine |
WO2000056298A2 (en) * | 1999-03-19 | 2000-09-28 | Luitpold Pharmaceuticals, Inc. | Treatment of lyme disease with polysulfated glycosaminoglycan formulations |
WO2000078345A1 (en) * | 1999-06-21 | 2000-12-28 | Milkhaus Laboratory, Inc. | Method for treatment of lyme disease |
ES2298249T3 (es) | 2000-08-18 | 2008-05-16 | Research Foundation Of State University Of New York | Ospa modificada de borrelia burgdorferi. |
US7847084B2 (en) | 2002-12-20 | 2010-12-07 | Board Of Regents, The University Of Texas System | VMP-like sequences of pathogenic Borrelia species and strains |
SG176451A1 (en) | 2006-11-03 | 2011-12-29 | Schering Plough Ltd | Canine lyme disease vaccine |
EP2361930A3 (en) | 2007-03-26 | 2011-10-26 | Dako Denmark A/S | Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases |
EP2167536A1 (en) | 2007-07-03 | 2010-03-31 | Dako Denmark A/S | Mhc multimers, methods for their generation, labeling and use |
US10611818B2 (en) | 2007-09-27 | 2020-04-07 | Agilent Technologies, Inc. | MHC multimers in tuberculosis diagnostics, vaccine and therapeutics |
US10968269B1 (en) | 2008-02-28 | 2021-04-06 | Agilent Technologies, Inc. | MHC multimers in borrelia diagnostics and disease |
US10722562B2 (en) | 2008-07-23 | 2020-07-28 | Immudex Aps | Combinatorial analysis and repair |
GB0817244D0 (en) | 2008-09-20 | 2008-10-29 | Univ Cardiff | Use of a protein kinase inhibitor to detect immune cells, such as T cells |
US10369204B2 (en) | 2008-10-02 | 2019-08-06 | Dako Denmark A/S | Molecular vaccines for infectious disease |
US11992518B2 (en) | 2008-10-02 | 2024-05-28 | Agilent Technologies, Inc. | Molecular vaccines for infectious disease |
CA2781110C (en) * | 2009-11-17 | 2018-07-31 | Abaxis, Inc. | Peptides and methods for the detection of lyme disease antibodies |
US8758772B2 (en) | 2011-11-04 | 2014-06-24 | Abaxis, Inc. | Peptides and methods for the detection of lyme disease antibodies |
PL223175B1 (pl) | 2012-10-22 | 2016-10-31 | Inst Chemii Bioorganicznej Polskiej Akademii Nauk | Szczepionka przeciw boreliozie, konstrukt genetyczny, rekombinowane białko, sposób otrzymywania konstruktu genetycznego, sposób otrzymywania szczepionki, sposób otrzymywania rekombinowanych białek, zastosowanie rekombinowanych białek do wytwarzania szczepionki przeciwko boreliozie |
US9610336B1 (en) * | 2014-07-16 | 2017-04-04 | Amiram Katz | Immunotherapy for lyme disease |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK590288D0 (da) * | 1988-10-24 | 1988-10-24 | Symbicom Ab | Kemiske forbindelser |
US4772464A (en) | 1985-08-01 | 1988-09-20 | Miles Laboratories, Inc. | Protective antibodies to serotypic determinants of flagellar antigens |
US4888276A (en) | 1986-06-26 | 1989-12-19 | Minnesota Mining And Manufacturing Company | Method and composition for the diagnosis of Lyme disease |
US4721617A (en) | 1986-08-14 | 1988-01-26 | Regents Of The University Of Minnesota | Vaccine against lyme disease |
US5034515A (en) * | 1987-09-22 | 1991-07-23 | Wisconsin Alumni Research Foundation | Staphylococcal fibronectin receptor, monoclonal antibodies thereto and methods of use |
DE4015911A1 (de) * | 1989-09-19 | 1991-03-28 | Max Planck Gesellschaft | Impfstoff gegen die lyme-krankheit |
WO1991009870A1 (de) * | 1989-12-22 | 1991-07-11 | Mikrogen Molekularbiologische Entwicklungs-Gmbh | Immunologisch aktive proteine von borrelia burgdorferi, zusammenhängende testkits und impfstoff |
SG47447A1 (en) * | 1990-06-15 | 1998-04-17 | Univ Yale | Compositions and methods for the prevention and diagnosis of lyme disease |
ATE196425T1 (de) * | 1990-07-06 | 2000-10-15 | American Home Prod | Impfstoff gegen die lyme-krankheit |
CA2057536C (en) * | 1990-12-21 | 1999-10-26 | John J. Dunn | Cloning and expression of borrelia lipoproteins |
EP0877085A1 (en) * | 1991-08-15 | 1998-11-11 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | OspA protein of borrelia burgdorferi subgroups, encoding genes and vaccines |
WO1993004157A1 (en) * | 1991-08-27 | 1993-03-04 | Novo Nordisk A/S | Detergent compositions |
WO1993008299A1 (en) * | 1991-10-18 | 1993-04-29 | Connaught Laboratories Inc. | Preparation of recombinant borrelia proteins |
WO1993007897A1 (en) * | 1991-10-21 | 1993-04-29 | Medimmune, Inc. | Bacterial expression vectors containing dna encoding secretion signals of lipoproteins |
-
1990
- 1990-05-17 DE DE4015911A patent/DE4015911A1/de not_active Withdrawn
- 1990-09-07 HU HU905816A patent/HU212716B/hu not_active IP Right Cessation
- 1990-09-11 NZ NZ235260A patent/NZ235260A/xx unknown
- 1990-09-12 AU AU62444/90A patent/AU651560B2/en not_active Ceased
- 1990-09-18 EP EP94112143A patent/EP0643974B1/de not_active Expired - Lifetime
- 1990-09-18 AT AT94112144T patent/ATE191499T1/de not_active IP Right Cessation
- 1990-09-18 ES ES90117943T patent/ES2082812T3/es not_active Expired - Lifetime
- 1990-09-18 AT AT90117943T patent/ATE131732T1/de not_active IP Right Cessation
- 1990-09-18 DE DE59010863T patent/DE59010863D1/de not_active Expired - Fee Related
- 1990-09-18 SI SI9011773A patent/SI9011773B/sl not_active IP Right Cessation
- 1990-09-18 EP EP90117943A patent/EP0418827B1/de not_active Expired - Lifetime
- 1990-09-18 ES ES94112143T patent/ES2129551T3/es not_active Expired - Lifetime
- 1990-09-18 AT AT94112143T patent/ATE175576T1/de not_active IP Right Cessation
- 1990-09-18 DE DE59010888T patent/DE59010888D1/de not_active Expired - Fee Related
- 1990-09-18 IE IE337790A patent/IE903377A1/en not_active IP Right Cessation
- 1990-09-18 DK DK90117943.2T patent/DK0418827T3/da active
- 1990-09-18 PL PL90307358A patent/PL170229B1/pl not_active IP Right Cessation
- 1990-09-18 DE DE59009978T patent/DE59009978D1/de not_active Expired - Fee Related
- 1990-09-18 AT AT94112145T patent/ATE186646T1/de not_active IP Right Cessation
- 1990-09-18 CA CA002025597A patent/CA2025597C/en not_active Expired - Fee Related
- 1990-09-18 EP EP94112144A patent/EP0633313B1/de not_active Expired - Lifetime
- 1990-09-18 DK DK94112144T patent/DK0633313T3/da active
- 1990-09-18 EP EP94112145A patent/EP0633028B1/de not_active Expired - Lifetime
- 1990-09-18 ES ES94112144T patent/ES2145077T3/es not_active Expired - Lifetime
- 1990-09-18 NO NO19904062A patent/NO311767B1/no unknown
- 1990-09-18 YU YU177390A patent/YU48250B/sh unknown
- 1990-09-18 DK DK94112145T patent/DK0633028T3/da active
- 1990-09-18 DK DK94112143T patent/DK0643974T3/da active
- 1990-09-18 DE DE59010903T patent/DE59010903D1/de not_active Expired - Fee Related
- 1990-09-18 EP EP98105444A patent/EP0861664A3/de not_active Withdrawn
- 1990-09-18 PL PL90286918A patent/PL169804B1/pl not_active IP Right Cessation
- 1990-09-18 FI FI904597A patent/FI102248B1/fi not_active IP Right Cessation
- 1990-09-18 ES ES94112145T patent/ES2141182T3/es not_active Expired - Lifetime
- 1990-09-19 JP JP24765090A patent/JP3205932B2/ja not_active Expired - Fee Related
- 1990-09-19 SK SK1511-98A patent/SK283089B6/sk unknown
- 1990-09-19 CZ CS904560A patent/CZ284538B6/cs not_active IP Right Cessation
- 1990-09-19 US US07/585,310 patent/US5178859A/en not_active Expired - Lifetime
- 1990-09-19 CZ CZ95970A patent/CZ284616B6/cs not_active IP Right Cessation
- 1990-09-19 KR KR1019900014814A patent/KR100205462B1/ko not_active IP Right Cessation
- 1990-09-19 PT PT95349A patent/PT95349B/pt active IP Right Grant
- 1990-09-19 SK SK1510-98A patent/SK283088B6/sk unknown
- 1990-09-19 SK SK4560-90A patent/SK456090A3/sk unknown
-
1993
- 1993-05-27 US US08/068,063 patent/US5434077A/en not_active Expired - Fee Related
-
1994
- 1994-09-15 HR HR940545A patent/HRP940545B1/xx not_active IP Right Cessation
-
1995
- 1995-03-20 US US08/406,623 patent/US5780030A/en not_active Expired - Fee Related
- 1995-03-20 US US08/407,350 patent/US5686267A/en not_active Expired - Lifetime
- 1995-04-24 HU HU95P/P00108P patent/HU211228A9/hu unknown
-
1996
- 1996-02-14 GR GR960400397T patent/GR3018995T3/el unknown
-
1997
- 1997-03-12 YU YU9097A patent/YU49370B/sh unknown
-
1998
- 1998-02-13 HK HK98101147A patent/HK1002405A1/xx not_active IP Right Cessation
- 1998-02-23 US US09/027,843 patent/US5856447A/en not_active Expired - Fee Related
- 1998-08-29 KR KR1019980035375A patent/KR100202128B1/ko not_active IP Right Cessation
- 1998-12-23 HK HK98114958A patent/HK1013620A1/xx not_active IP Right Cessation
-
1999
- 1999-10-07 US US09/413,858 patent/US6613331B1/en not_active Expired - Fee Related
- 1999-11-30 GR GR990403104T patent/GR3032010T3/el unknown
-
2000
- 2000-06-14 GR GR20000401362T patent/GR3033675T3/el not_active IP Right Cessation
- 2000-07-26 JP JP2000225341A patent/JP3328644B2/ja not_active Expired - Fee Related
- 2000-12-11 JP JP2000376159A patent/JP3418171B2/ja not_active Expired - Fee Related
-
2001
- 2001-09-24 NO NO20014624A patent/NO315905B1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI9011773B (en) | Vaccine against lyme disease, process for obtaining it, monoclonal antibody, antigene, recombinant dna, recombinant vector and process for obtaining this antigene | |
Gadde et al. | Passive immunization with hyperimmune egg-yolk IgY as prophylaxis and therapy for poultry diseases–a review | |
Theisen et al. | Antigenicity and immunogenicity of recombinant glutamate-rich protein of Plasmodium falciparum expressed in Escherichia coli | |
Simon et al. | Recombinant outer surface protein A from Borrelia burgdorferi induces antibodies protective against spirochetal infection in mice | |
Schaible et al. | Monoclonal antibodies specific for the outer surface protein A (OspA) of Borrelia burgdorferi prevent Lyme borreliosis in severe combined immunodeficiency (scid) mice. | |
Hanson et al. | Active and passive immunity against Borrelia burgdorferi decorin binding protein A (DbpA) protects against infection | |
Stüber et al. | System for High-Level Production in Escherichia coli and Rapid Purification of Recombinant Proteins: Application to Epitope Mapping, Preparation of Antibodies, and Structure—Function Analysis | |
Fahey et al. | Virus-neutralizing and passively protective monoclonal antibodies to infectious bursal disease virus of chickens | |
Berghman et al. | Antibodies: an alternative for antibiotics? | |
Vidotto et al. | Intermolecular relationships of major surface proteins of Anaplasma marginale | |
Shivachandra et al. | Immunogenicity of highly conserved recombinant VacJ outer membrane lipoprotein of Pasteurella multocida | |
CN104168918A (zh) | 含有t-细胞表位的b细胞受体复合体结合蛋白质 | |
CN107586335A (zh) | 一种人源化单克隆抗体及应用 | |
Gogolewski et al. | Protective ability of antibodies against 78-and 40-kilodalton outer membrane antigens of Haemophilus somnus | |
EP3151858A2 (en) | Antibody guided vaccines and methods of use for generation of rapid mature immune responses | |
JP2016515516A5 (sh) | ||
WO2014043215A1 (en) | Bi-specifc diabodies for masking and targeting vaccines | |
Woollard et al. | Synthetic peptides induce antibody against a host-protective antigen of Echinococcus granulosus | |
Nasiri et al. | Production and characterization of egg yolk antibody (IgY) against recombinant VP8-S2 antigen | |
DE69737323D1 (de) | Adhesin aus heliobacter pylori, welches an blutgruppenantigene bindet | |
Bagdasarian et al. | Immunogenicity of Actinobacillus ApxIA toxin epitopes fused to the E. coli heat-labile enterotoxin B subunit | |
Klemm et al. | Prediction of antigenic determinants and secondary structures of the K88 and CFA1 fimbrial proteins from enteropathogenic Escherichia coli | |
Bailey et al. | Production of murine monoclonal antibodies to the major axial filament polypeptide of Treponema pallidum | |
Romito et al. | Eliciting antigen-specific egg-yolk IgY with naked DNA | |
Agterberg et al. | Protection of guinea-pigs against foot-and-mouth disease virus by immunization with a PhoE-FMDV hybrid protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
IF | Valid on the event date | ||
KO00 | Lapse of patent |
Effective date: 20060515 |